Table 3.

Multivariable Cox shared frailty models for death-censored technique failure defined as 30 and 180 days

Covariates	Technique Failure 30 d			Technique Failure 180 d
	HR	95% CI	P Value	HR	95% CI	P Value
Era (2004–2009)	1.0	Reference		1.0	Reference
Era (2010–2014)	0.93	0.86 to 0.99	0.04	0.82	0.75 to 0.89	<0.001
Patient-level characteristics
Age (decade)	0.93	0.91 to 0.96	<0.001	0.93	0.90 to 0.96	<0.001
Men	1.07	0.98 to 1.14	0.06	1.12	1.04 to 1.22	<0.01
Race			<0.001			<0.001
White	1.00	Reference		1.00	Reference
Asian	0.79	0.70 to 0.89	<0.001	0.80	0.70 to 0.92	0.002
ATSI	1.12	0.97 to 1.30	0.12	1.19	1.01 to 1.40	0.04
MP	0.85	0.69 to 1.03	0.10	0.86	0.68 to 1.08	0.19
Other	0.67	0.52 to 0.87	0.003	0.67	0.50 to 0.90	<0.01
BMI, kg/m2			<0.001			<0.001
<18.5	1.06	0.88 to 1.30	0.53	1.0	0.79 to 1.25	0.99
18.5–24.9	1.00	Reference		1.00	Reference
25–29.9	1.08	0.99 to 1.17	0.07	1.04	0.95 to 1.14	0.41
≥30	1.27	1.17 to 1.39	<0.001	1.32	1.20 to 1.46	<0.001
Smoking status			0.03			0.08
Nonsmoker	1.00	Reference		1.00	Reference
Current smoker	1.09	0.98 to 1.21	0.10	1.08	0.96 to 1.22	0.19
Former smoker	1.10	1.02 to 1.19	0.01	1.10	1.00 to 1.20	0.03
Diabetes mellitus	0.98	0.87 to 1.10	0.73	1.01	0.89 to 1.16	0.87
Cardiovascular disease	1.12	1.04 to 1.21	0.003	1.08	0.99 to 1.18	0.07
Chronic lung disease	1.05	0.96 to 1.16	0.29	0.98	0.88 to 1.10	0.75
Primary renal disease			<0.001			0.004
GN	1.00	Reference		1.00	Reference
Diabetes nephropathy	0.98	0.86 to 1.11	0.73	0.96	0.82 to 1.11	0.54
Hypertension	0.83	0.74 to 0.94	0.002	0.86	0.75 to 0.98	0.02
Polycystic kidney disease	1.20	1.04 to 1.38	0.01	1.11	0.94 to 1.31	0.22
Other/unknown	0.86	0.78 to 0.95	0.003	0.85	0.76 to 0.95	<0.01
Late referral	1.06	0.98 to 1.16	0.15	1.02	0.92 to 1.23	0.71
Initial modality of RRT (PD)a
Overall	0.69	0.63 to 0.76	<0.001	0.70	0.62 to 0.79	<0.001
At 6 mo	0.73	0.67 to 0.79	<0.001	0.73	0.66 to 0.80	<0.001
At 1 yr	0.76	0.70 to 0.82	<0.001	0.76	0.70 to 0.83	<0.001
At 2 yr	0.84	0.78 to 0.91	<0.001	0.82	0.75 to 0.90	<0.001
Initial PD modality (CAPD)	0.98	0.90 to 1.07	0.70	0.86	0.80 to 0.93	<0.001
IRSAD scoresb			0.91			0.71
<934	1.00	Reference		1.00	Reference
934–983	1.02	0.93 to 1.12	0.66	1.03	0.93 to 1.15	0.52
>983–1032	1.02	0.93 to 1.13	0.64	1.05	0.94 to 1.17	0.39
>1032	0.99	0.90 to 1.09	0.90	0.99	0.88 to 1.11	0.91
Center-level characteristics
Transplant center	1.06	0.90 to 1.25	0.52	1.05	0.89 to 1.25	0.54
Center size (incident patients per 1 yr)			0.004			<0.001
<16	1.19	1.03 to 1.38	0.02	1.23	1.07 to 1.43	<0.01
16–48	1.00	Reference		1.00	Reference
>48	0.77	0.60 to 0.98	0.03	0.79	0.63 to 0.99	0.04
APD exposure,c %			0.15			0.04
<41	1.17	0.99 to 1.39	0.07	1.14	0.97 to 1.35	0.11
41–71	1.00	Reference		1.00	Reference
>71	1.11	0.95 to 1.31	0.17	1.22	1.04 to 1.42	0.01
Icodextrin use,c %			0.69			0.68
<35	0.93	0.78 to 1.12	0.47	0.94	0.79 to 1.22	0.50
35–67	1.00	Reference		1.00	Reference
>67	0.95	0.81 to 1.11	0.53	0.94	0.81 to 1.10	0.46
Phosphate in target,c %			0.32			0.66
<40	1.14	0.96 to 1.37	0.14	1.08	0.91 to 1.29	0.37
40–46	1.00	Reference		1.00	Reference
>46	1.02	0.86 to 1.21	0.80	1.05	0.89 to 1.24	0.60
Antifungal use,d %			0.32			0.47
<38	0.98	0.83 to 1.16	0.81	0.95	0.80 to 1.11	0.50
38–86	1.00	Reference		1.00	Reference
>86	1.14	0.94 to 1.36	0.18	1.07	0.90 to 1.29	0.44

HR, hazard ratio; 95% CI, 95% confidence interval; ATSI, Aboriginal and Torres Strait Islander; MP, Maori–Pacific Islanders; BMI, body mass index; PD, peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; IRSAD, Index of Relative Socioeconomic Advantage and Disadvantage; APD, automated peritoneal dialysis.

^aThere was a significant interaction between initial modality of RRT and time (P<0.001). The overall HR and HR at three time points are given.

^bSocioeconomic position reported as IRSAD scores, with higher scores reflecting higher socioeconomic position.

^cPercentage of all participating patients in the center.

^dPercentage of peritonitis in center.